Get the Stockscreener App
403.30
1.36%
-5.55
After Hours:
403.55
0.25
+0.06%
Vertex Pharmaceuticals Inc stock is traded at $403.30, with a volume of 1.32M.
It is down -1.36% in the last 24 hours and up +1.68% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$408.85
Open:
$411.72
24h Volume:
1.32M
Relative Volume:
0.75
Market Cap:
$103.40B
Revenue:
$11.39B
Net Income/Loss:
$3.64B
P/E Ratio:
28.83
EPS:
13.9904
Net Cash Flow:
$3.50B
1W Performance:
+4.55%
1M Performance:
+1.68%
6M Performance:
-16.68%
1Y Performance:
-11.08%
1-Day Range:
$403.04
$411.91
1-Week Range:
$384.39
$411.91
52-Week Range:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
403.30 | 104.83B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.00 | 63.59B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.35 | 60.43B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
800.00 | 48.45B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
343.87 | 37.91B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Insider Sell: Jonathan Biller Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades' - Benzinga
With Emma Walmsley exiting GSK, who will be pharma’s top women CEOs? - PharmaVoice
Vertex Pharmaceuticals (VRTX): Assessing Valuation as Shares Hold Steady and Long-Term Prospects Remain Key - Yahoo Finance
Is Vertex Pharmaceuticals Incorporated (VX1) stock overpriced at current multiplesJuly 2025 Update & Free Long-Term Investment Growth Plans - newser.com
Is Vertex Pharmaceuticals Incorporated reversing from oversold territoryMarket Performance Recap & Reliable Breakout Forecasts - newser.com
Will Vertex Pharmaceuticals Incorporated (VX1) stock outperform value peersMarket Performance Report & Weekly Breakout Opportunity Watchlist - newser.com
Why Vertex Pharmaceuticals Incorporated (VX1) stock signals breakout potentialTrade Exit Summary & Low Risk Profit Maximizing Plans - newser.com
Chart based exit strategy for Vertex Pharmaceuticals IncorporatedMarket Sentiment Summary & Technical Entry and Exit Tips - newser.com
Can Vertex Pharmaceuticals Incorporated stock resist sector downturnsEarnings Trend Report & Technical Buy Zone Confirmation - newser.com
Why Vertex Pharmaceuticals Incorporated (VX1) stock remains top ratedBear Alert & Daily Market Momentum Tracking - newser.com
What MACD signals say about Vertex Pharmaceuticals IncorporatedJuly 2025 Pullbacks & Low Volatility Stock Suggestions - newser.com
Will Vertex Pharmaceuticals Incorporated price bounce be sustainablePortfolio Profit Report & Long Hold Capital Preservation Tips - newser.com
Published on: 2025-10-03 02:22:36 - newser.com
Why Vertex Pharmaceuticals Incorporated (VX1) stock could outperform next yearRecession Risk & Safe Entry Trade Signal Reports - newser.com
Published on: 2025-10-03 01:57:58 - newser.com
News impact scoring models applied to Vertex Pharmaceuticals IncorporatedJuly 2025 Institutional & Weekly Breakout Watchlists - newser.com
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Highlights Pipeline Progress at BofA Global Healthcare Conference - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Receives Raised Price Target from Citigroup | VRTX Stock News - GuruFocus
Diabetic Peripheral Neuropathy Market Expected to Experience Major Growth by 2034, According to DelveInsight | Grünenthal, Averitas Pharma, Daiichi Sankyo, Vertex Pharma, Helixmith, Lexicon Pharma - Barchart.com
Published on: 2025-10-01 09:22:12 - newser.com
What Does the Market Think About Vertex Pharmaceuticals Inc? - Sahm
Will Vertex Pharmaceuticals Incorporated (VX1) stock remain on Wall Street radarJuly 2025 Market Mood & Safe Entry Momentum Tips - newser.com
Lee Johnson Capital Management LLC Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
GC Wealth Management RIA LLC Buys 1,314 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Published on: 2025-09-30 02:36:28 - newser.com
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
GSK CEO Emma Walmsley’s Departure Reseals Pharma’s Glass Ceiling - BioSpace
Is Vertex Pharmaceuticals Incorporated a good long term investmentGlobal Market Influence & Low Cost Market Tips - earlytimes.in
SWS Partners Has $1.11 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
V Square Quantitative Management LLC Buys 1,875 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Moody Lynn & Lieberson LLC Boosts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
What drives Vertex Pharmaceuticals Incorporated VX1 stock priceEarnings Beat Highlights & Outstanding Portfolio Tips - earlytimes.in
Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug - msn.com
Leerink Partnrs Brokers Lower Earnings Estimates for VRTX - MarketBeat
What analysts say about Vertex Pharmaceuticals Incorporated VX1 stockTechnical Breakout Signals & Small Entry Capital Stocks - Early Times
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
1.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):